



6 September 2021

ASX Announcement

Development Application approval received for R&D facilities at Smithfield

- Development Application approval received for 165 Woodpark Road, Smithfield, NSW
- Construction re-commenced at Star Combo's TGA-licensed nutraceutical manufacturing site, 171 Woodpark Road, which will increase production capacity by 100% once complete

Star Combo Pharma Limited (ASX: S66) (Star Combo) is pleased to provide an update on the existing site expansion and the recent approval on the adjacent 165 Woodpark Road in Smithfield, New South Wales.

Star Combo has received approval for its Development Application from Cumberland City Council to begin works at its site at 165 Woodpark Road, Smithfield. The site was purchased in August last year and the development project of this new multi-level complex will accommodate a modern, purpose-built R&D and Test Laboratory Centre. The development project supports Star Combo's strategy to become a leading contract manufacturer in Australia's premium vitamins and dietary supplements sector.

Star Combo CEO Su Zhang said, "This is a really positive development for Star Combo as we move one step closer to completing our manufacturing facilities upgrade. Once complete, the R&D and Test Laboratory centre will enable us to extend our service offering and support our existing OEM customers. It will significantly enhance our capability to develop new and innovative products to address the growing demand in both local and overseas markets for vitamins and dietary supplements. These new and innovative products, by their nature will attract a higher margin so as we grow this aspect of the business, we expect it to become increasingly profitable."

Star Combo has re-commenced the expansion of its current facilities at its TGA-licensed nutraceutical manufacturing site at 171 Woodpark Road, Smithfield after works were put on hold in July due to the COVID-19 pandemic restrictions. Expansion plans underway at this site involve upgrading the existing facility and installation of 13 new production lines. Once complete, the upgraded site is expected to significantly increase production capacity and will enable Star Combo to cost effectively address the growing demand in both local and overseas markets for Australian made premium vitamins and dietary supplements. \$3.4M has been invested to date and the facilities are on track to be completed in 2022 despite the delays caused by the pandemic.



-ENDS-

This ASX announcement has been approved by the Star Combo Pharma's Board of Directors.

Investor relations contact

Su Zhang - CEO

investors@starcombo.com.au

Media relations contact

WE Communications

Kate Burrell

T: 0438 680 628

WE-AUS66@we-worldwide.com

About Star Combo Pharma

Star Combo Pharma Ltd (ASX: S66) is a Sydney based contract manufacturer of vitamins, health and beauty products with a portfolio of own brands and distribution capabilities. Our products are made from natural ingredients with scientific R&D and adheres to the highest manufacturing practices governed by the Therapeutic Goods Administration. Star Combo has offices in China and currently supplies the Australian pharmacy network through 450 Terry White Chemmart stores as well as wholesale customers in Australia and China. Directed by pharmacist and experts in health supplement manufacturing, Star Combo's vision is to be the leading manufacturer of premium vitamins and dietary supplements in Australia. Since its establishment in 2004, Star Combo has demonstrated strong product and business development and continues to expand our current operations to serve our loyal business partners, customers and employees.